With the approval of Livdelzi, Gilead Sciences is growing its liver disease portfolio. Livdelzi is used to treat primary biliary cholangitis (PBC), a rare liver disease that occurs when your body’s immune system incorrectly attacks your bile ducts.
Even though this is the company’s first inflammatory drug launch, the drug fits nicely into its mission to fight liver diseases and its therapeutic area focuses of virology, oncology, and inflammation.
Click here to read the entire article.